Strata Critical Medical Inc

SRTA

Valor de mercado US$ 402 mi

NEW YORK, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Strata Critical Medical, Inc. (Nasdaq: SRTA, “Strata” or the “Company”), today announced that management will present at the 2026 Jefferies Healthcare Services and Technology Conference on Monday, September 14, 2026, at 2:15 pm ET. A webcast of the event will be available at the link here. A replay will be available shortly after the conclusion of the presentation on the investor relations section of the Company's website at https://ir.stratacritical.com/.

Strata Critical Medical, Inc. (SRTA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

The mean of analysts' price targets for Strata Critical Medical, Inc. (SRTA) points to a 47.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Strata Critical Medical, Inc. (SRTA) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

The consensus price target hints at a 60% upside potential for Strata Critical Medical, Inc. (SRTA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Strata Critical Medical, Inc. (SRTA) Q2 2026 Earnings Call Transcript

Revenue increased 60.7% year-over-year to $72.5 million in Q2 2026 Clinical revenue increased 22.6% sequentially in Q2 2026; Excluding Clinical acquisitions that closed in Q2 2026, Clinical revenue increased 15.1% sequentially driven by a 23.8% increase in Transplant Clinical revenue Q2 2026 net loss from continuing operations of $(10.5) million or (14.5)% of revenue Adjusted EBITDA (1) of $7.9 million in Q2 2026; Adjusted EBITDA margin of 10.9% Cash flow from operating activities was $5.7 million in Q2 2026; Free Cash Flow (1) was $2.9 million in Q2 2026 Completed bolt-on acquisitions of Louisville Perfusion Services, Heart and Lung Transplant National Recovery Program and Ohio Valley Perfusion Associates during Q2 2026 Signed agreement to take over Statline's Transplant Center Organ Placement customer relationships on a rolling basis over the next year NEW YORK, Aug. 04, 2026 (GLOBE NEWSWIRE) -- Strata Critical Medical, Inc. (Nasdaq: SRTA, "Strata" or the "Company"), today announced financial results for the second quarter ended June 30, 2026. Financial results in this release, including all comparisons to prior year periods, reflect continuing operations only.

NEW YORK, July 21, 2026 (GLOBE NEWSWIRE) -- Strata Critical Medical. (Nasdaq: SRTA, “Strata” or the “Company”), will release financial results for the second quarter ended July 31, 2026 on Tuesday, August 4, 2026 before the market opens. The company will hold a conference call on the same day at 8:00 am Eastern Time to discuss the results. The call will be hosted by Melissa Tomkiel, Strata's Co-Chief Executive Officer and General Counsel, and Will Heyburn, Strata's Co-Chief Executive Officer and Chief Financial Officer, and will include a question-and-answer session for call participants.

Strata Critical Medical is rated a buy, driven by expanding market share, operational efficiencies, and a comprehensive suite of transplant logistics and clinical services. SRTA's asset-light-to-moderate model, strategic acquisitions, and focus on NRP technology position it to benefit from industry consolidation and secular tailwinds. Gross margin improvement is a key near-term catalyst, with management incentivized to reach 25% margins by 2027; Q1 2026 gross margin reached 21%.

Network of experienced transplant surgeons in key markets will immediately become available to all Strata customers Adds significant scale to Transplant Clinical, Strata's fastest growing business line, with a similar, rapid growth trajectory $21.5 million acquisition completed at mid-single-digit multiple of Adjusted EBITDA, pre-synergy, consistent with Strata's capital deployment strategy NEW YORK, June 24, 2026 (GLOBE NEWSWIRE) -- Strata Critical Medical, Inc. (Nasdaq: SRTA, “Strata” or the “Company”), today announced that it has completed the acquisition of Heart and Lung Transplant National Recovery Program (“HLT-NRP”), a provider of transplant surgical recovery services in the United States. “HLT-NRP strengthens our organ recovery platform by significantly increasing our network of experienced transplant surgeons available to complete recoveries across the country adding clinical depth and geographic reach in key markets such as Florida and California,” said Will Heyburn, Co-CEO of Strata.